Severe migraine sufferers get new hopes with Erenumab, after undergoing number of unsuccessful treatments, claims a recent preliminary study disclosed Tuesday.
The new drug – erenumab is one of the human monoclonal antibodies, which restrains the calcitonin gene-related peptide, a molecule exists in the human body in two forms as α-CGRP and β-CGRP. Calcitonin gene-related peptide delivers the intensely painful migraine signals when the body suffers an attack. This drug is the long enduring injection intended to end the migraine attack even before it gets triggered.
Dr. Uwe Reuter said in a news release by the American Academy of Neurology (AAN) that, “Working with a group of people with tough-to-treat migraine, the study found that erenumab reduced the average number of monthly migraine headaches by more than 50 percent for nearly a third of study participants.”
Treatment with using some monoclonal antibody and erenumab over migraine attack is known as the fremanezumab, which has been recently submitted for being approved by the U.S. Food and Drug Administration and the drug regulators of Europe. Dr. Uwe Reuter from the Charite University Medicine Berlin in Germany is the leading researcher of the study.
An adjunct neurologist, Dr. Randall Berliner from the Lenox Hill Hospital in New York City, who is not involved in the new research, says “We have a new class of drugs — erenumab likely to be the first to be on the market — that are showing great promise in preventing migraine attacks. Our bodies typically produce antibodies to fight off infections, cancers and other foreign agents that the immune system deems harmful.”